AstraZeneca PLC Sponsored BDR (A1ZN34)

Overview

AstraZeneca PLC is a global biopharmaceutical entity committed to the exploration, creation, production, and promotion of prescription medications. Originating as Zeneca Group PLC, the company underwent a name change to AstraZeneca PLC in April 1999, marking a significant milestone in its history. Since its foundation in 1992, AstraZeneca has established a robust presence in the healthcare sector, specifically in the development of innovative therapeutic solutions. Headquartered in Cambridge, United Kingdom, AstraZeneca reaches a broad spectrum of patients worldwide through its extensive network of distributors and local representative offices. These branches span across various continents including the United Kingdom, Europe, the Americas, Asia, Africa, and Australasia, ensuring the company's global footprint. Additionally, AstraZeneca engages in strategic collaborations to enhance its drug discovery and development capabilities, as evidenced by its agreements with Neurimmune AG and BenevolentAI, focusing on systemic lupus erythematosus and other significant health challenges.

Products and Services

AstraZeneca's product portfolio is impressive, covering a wide range of therapeutic areas such as cardiovascular diseases, renal and metabolic disorders, oncology, and rare diseases, including treatments for COVID-19.

• Cardiovascular, Renal, and Metabolism: Farxiga, Brilinta, Lokelma, and Roxadustat are some of the key products in this category, targeting diseases like heart failure, thrombosis, and chronic kidney disease.
• Oncology: In the realm of cancer treatment, AstraZeneca offers Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, and Orpathys, addressing various types of cancer through innovative therapies.
• Rare Diseases and COVID-19: The company's response to the pandemic and rare diseases includes Vaxzevria and Beyfortus for COVID-19, alongside Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma, catering to different rare diseases.
• Respiratory and Immunology: AstraZeneca is also a key player in the treatment of respiratory conditions and immunological disorders, with products like Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp making significant impacts.

In addition to these, AstraZeneca is engaged in ongoing research and development efforts, aimed at addressing the unmet medical needs of patients around the world. The company's strategic collaborations and its diverse product range demonstrate AstraZeneca's commitment to innovation in healthcare and its dedication to improving patient outcomes across the globe.